<DOC>
	<DOCNO>NCT02230241</DOCNO>
	<brief_summary>This multi-center survey patient currently receive lipid-lowering medication moderate high cardiovascular ( CV ) risk . The survey conduct Russian Federation . Data collection study subject do within one physician visit . If enrol subject come visit fasting ( least 8 hour ) , appointment blood test make another day .</brief_summary>
	<brief_title>CEntralized Pan-Russian Survey tHE Undertreatment hypercholeSterolemia II ( CEPHEUS II )</brief_title>
	<detailed_description>This multi-center survey patient currently receive lipid-lowering medication moderate high CV risk . The survey conduct Russian Federation . Data collection study subject do within one physician visit . If enrol subject come visit fasting ( least 8 hour ) , appointment blood test make another day . Prior assessment first subject site , investigator complete investigator questionnaire his/her experience perception management hypercholesterolemia his/her patient . Prior assessment , subject record patient questionnaire awareness hypercholesterolemia , current treatment schedule , perception , compliance . The investigator complete Case Report Form ( CRF ) subject 's demographic , know cardiovascular risk factor , cardiovascular medical history , current lipid-lowering drug therapy , reason therapy . Fasting blood sample take tubes test total cholesterol , low-density lipoprotein cholesterol ( LDL ) , high-density lipoprotein cholesterol ( HDL ) , glucose , creatinine , hemoglobin A1c , hemoglobin , hematocrit central laboratory Russian Federation .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Properly obtain write informed consent potential subject . On lipidlowering drug therapy least 3 month ( 90 day ) , dose change minimum 8 week ( 56 day ) . Scheduled blood test total cholesterol ( TC ) , HDLC , LDLC , glucose , creatinine , HbA1c , Hb , hematocrit visit consider survey participation , test must decide necessary studyunrelated purpose visit . Subjects unwilling unable provide write informed consent . The cognitive status potential subject and/or home environment ( investigator 's opinion ) might compromise compliance treatment regimen past 8 week . A low CV risk . Participating clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Dyslipidaemia</keyword>
	<keyword>LDL-C goal</keyword>
	<keyword>Guidelines</keyword>
</DOC>